EICHORCondition: Relapsing Remitting Multiple Sclerosis · Sponsor: TG Therapeutics, Inc.
This study evaluates the long term use of a single agent ublituximab, a novel monoclonal antibody, in patients with relapsing forms of multiple sclerosis
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Subjects currently enrolled in TG1101-RMS201 trial * Subjects who have completed three infusions of ublituximab (at Day 1, Day 15, and Week24, as specified in the TG1101-RMS201 protocol) and have completed the scheduled assessments up to the final 48-week visit Exclusion Criteria: * Subjects who discontinued ublituximab treatment or withdrew consent from the TG1101- RMS201 study during the 48-week evaluation period * Subjects who have started any other immunomodulating or disease modifying therapy after completion of the TG1101-RMS201 trial * Pregnant or nursing mothers
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| TG Therapeutics Investigational Trial Site | Pasadena, California, United States | — |
| TG Therapeutics Investigational Trial Site | Aurora, Colorado, United States | — |
| TG Therapeutics Investigational Trial Site | Lexington, Kentucky, United States | — |
| TG Therapeutics Investigational Trial Site | Columbus, Ohio, United States | — |
| TG Therapeutics Investigational Trial Site | Westerville, Ohio, United States | — |
| TG Therapeutics Investigational Trial Site | Knoxville, Tennessee, United States | — |
| TG Therapeutics Investigational Trial Site | Round Rock, Texas, United States | — |
| TG Therapeutics Investigational Trial Site | San Antonio, Texas, United States | — |
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03381170